Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study
Keyword(s):
Phase 2
◽
Keyword(s):
2000 ◽
Vol 95
(12)
◽
pp. 3579-3583
◽
Keyword(s):
2021 ◽